STAT+: Democratic senators raise concerns with potential FDA pick
WASHINGTON — Sens. Joe Manchin and Richard Blumenthal have concerns with President Biden’s rumored nominee…
Category: STAT+
STAT+: STAT+ Conversation: Pain and Promise: Examining a Fibromyalgia Blood Test
Editor’s note: A livestream of the conversation will be embedded below at 1 p.m. ET….
STAT+: Pharmalittle: FDA panel to review Pfizer Covid shot for kids; Novartis may sell or spin off its Sandoz generic unit
Good morning, everyone, and how are you today? A spot of rain, and then some,…
STAT+: Licensing biotech breakthroughs is a contentious, painful slog. Can the process be fixed?
Students, employees, and professors at a research institution generally pledge that in the event they…
STAT+: ‘For good rather than evil’: Mark Cuban and an employer’s coalition to launch new PBMs to lower drug costs
As Americans grapple with prescription drug costs, two new companies are being launched in hopes…
STAT+: In research on mice, scientists use light to paint to a more precise target for CAR-T to attack tumors
In a dark lab, a sedated mouse laid face down on the counter, its backside…
STAT+: Pharmalittle: Most pharma money went to Dems holding up drug-pricing reform; European officials raid pharma animal health company
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Eight years after a landmark Supreme Court ruling on DNA ownership, its ramifications are becoming clearer
Today, if you want to know what scary family health secrets lay buried in your…
STAT+: The stirrings of revolt: Hospitals nationwide are sidestepping health record giants to better harness patient data
A small group of software vendors has largely controlled the flow of patient data in…
STAT+: 3 pressing questions on 23andMe’s pivot into primary care
The genetic testing company 23andMe said Friday it will acquire the telehealth and pharmacy startup…
STAT+: Pharmalittle: Four Democratic senators may delay Medicare drug price reform; Western Covid vaccine stockpiles to hit 600M doses by year’s end
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Illumina will launch Grail’s cancer detection test in Africa and Asia — but doesn’t know when
Sequencing company Illumina is planning to launch Galleri — the much-hyped cancer detection test from…
STAT+: Could wearable tech — and AI — change how we diagnose infants with conditions like cerebral palsy?
An unlikely team of engineers and mobility researchers has developed an experimental set of small,…
STAT+: The four senators who could make or break Democrats’ drug pricing ambitions
WASHINGTON — The fate of the Democratic party’s ambitious goal of allowing Medicare to negotiate…
STAT+: FDA warns a hospital and two physicians for putting patients at ‘significantly increased’ risk in trials
In harsh tones, U.S. regulators warned a Minnesota hospital and two of its physicians for…
STAT+: Most women had no issues obtaining abortion pill from mail-order pharmacies
Amid national furor over abortion access, a new survey found most women were satisfied with…
STAT+: Pharmalittle: Power for Medicare to negotiate drug prices grows less likely; FDA OKs mix-and-match Covid booster shots
Top of the morning to you. And a fine one it is. Crystal clear blue…
.jpg)
STAT+: MIT professor sues after he was forced to resign from institute following sexual harassment allegations
A prominent Massachusetts Institute of Technology biology professor who was forced two months ago to resign from…
STAT+: Amid a health tech consolidation wave, Everly Health acquires fertility startup Natalist
Riding a wave of consolidation in virtual care, home diagnostics brand Everly Health on Thursday…
STAT+: A disrupting force, or ‘just another mail order pharmacy’? How Amazon Pharmacy stacks up a year after launching
It was the launch that sent pharmacy stocks into a tailspin. Within hours of Amazon…
STAT+: Senate Democrats push back on the notion that adding dental, vision to Medicare would bankrupt it
Key Senate Democrats used a hearing Wednesday to push back on the argument that expanding…
STAT+: Pulling back the curtain: U.K. to launch new system for registering clinical trials automatically
In its latest bid to boost clinical trial transparency, the U.K. government will automatically register…
STAT+: Pharmalittle: Gates commits $120 million to speed generic versions of Merck Covid-19 pill; sales of Biogen Alzheimer’s drug bomb
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
STAT+: Takeda strikes a rebate deal for lung cancer drug as health plans look to value-based agreements
In another bid to address the cost of prescription medicines, Takeda Pharmaceuticals (TAK) and 32PointHealth…
STAT+: Biogen’s Aduhelm sales fall dramatically below Wall Street’s expectations
Biogen made just $300,000 from the Alzheimer’s disease treatment Aduhelm in the first full quarter…
STAT+: In a sea of skeptics, this physician was one of fibromyalgia patients’ few true allies. Or was he?
Cindy Bradley-Graziadei almost didn’t take the test. By the time she saw it advertised, in…
STAT+: Pharmalittle: WHO hopes to buy Covid treatments for $10 a course; Sinema is a big obstacle to drug pricing reform
Rise and shine, another busy day is on the way. However, this is also shaping…
STAT+: Underpinning Sinema’s outspoken opposition to major drug pricing reforms: her close ties to Arizona biotechs
Phoenix, Ariz. is no Kendall Square. Its biotech companies, ventures like OncoMyx Therapeutics and VisionGate,…
STAT+: Amazon is beefing up its health care lobbying operation
WASHINGTON — Amazon is bulking up its efforts to influence health care policy at the…
.jpg)
STAT+: UnitedHealthcare launches a virtual-first health insurance plan as hybrid care gains steam
The pandemic prompted a mad dash to figure out how to deliver health care virtually….
STAT+: FDA approves an interchangeable biosimilar version of Humira, but health care savings are dubious
For the first time, U.S. regulators have approved an interchangeable, biosimilar version of Humira, a…
STAT+: An FDA rejection derails Omeros, exposing the empty promises of its CEO
It’s remarkable to watch Omeros CEO Greg Demopulos and his executive team dissolve into a…
STAT+: ‘I don’t know anybody who wants their health disrupted’: Ken Frazier steps out in new venture capital role
Former Merck CEO Ken Frazier, famous for building the drugmaker into one of the world’s…
STAT+: Pharmalittle: Biogen drug for rare form of ALS fails pivotal study; EU criticized over IP stance at WTO
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: The new vision for the now-merged Doctor on Demand and Grand Rounds begins to take shape
In May, two privately held health tech startups — Doctor on Demand and Grand Rounds…
STAT+: ‘My jaw dropped’: Basic security flaws in third-party apps leave millions of patient records at risk
In the last year, cyberattacks on hospitals have surged, putting a spotlight on the need…
STAT+: Illuminating the black box: Five ways the FDA could build transparency into AI devices
Artificial intelligence tools in health care should be safe and effective. They should be fair…
STAT+: Biogen drug for rare form of ALS fails pivotal study — another setback for fatal disease with few treatments
Biogen reported disappointing results Sunday from a late-stage clinical trial involving its experimental treatment for…
STAT+: Pharmalittle: FDA panel recommends Moderna Covid booster shots; Biden eyes Califf as FDA commish
And so, another working week will soon draw to a close. Not a moment too…
STAT+: MD Anderson hit with ethics complaint over failure to disclose clinical trial results
An advocacy group has filed an ethics complaint with the University of Texas MD Anderson…
STAT+: Is Robert Califf a savvy choice to helm the FDA — again?
WASHINGTON — The Food and Drug Administration has been without a permanent leader for 10…
STAT+: New CRISPR tools could fix diseases caused by large DNA rearrangements, scientists report
Ever since the now Nobel-winning discovery of CRISPR genome editing in 2020, scientists have been…
STAT+: Pharmalittle: Biden team warns Moderna over global supplies of Covid-19 shot; Pfizer uses a warranty for refunds when a cancer drug fails
Rise and shine. Another busy day is on the way. Indeed, the official to-do list…
STAT+: A new startup ventures to make its mark in the virtual primary care market
As the digital health sector teems with new entrants, another virtual care startup is stepping…
STAT+: In its search for a new FDA commissioner, the White House is relying on insiders for advice
WASHINGTON — Ten months into his tenure, President Biden has yet to nominate anyone to…
STAT+: Buoyed by its popular weight loss app, Noom enters the crowded field of digital mental health
Five months ago, weight loss company Noom announced $540 million in funding, dwarfing its previous…
STAT+: Pfizer will use a warranty to refund the cost of a lung cancer drug if it doesn’t work
In an unusual bid to address prescription drug costs, Pfizer (PFE) is promising to offer…
STAT+: Pharmalittle: FDA scientists uncertain about Moderna vaccine boosters; pharma may face stricter rules for supplying meds in the EU
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
STAT+: Big Health scores a novel deal to bring its digital therapeutics to an entire country
Part of the allure of software-based medical treatments is the possibility of reaching people in…
STAT+: New data on CRISPR Therapeutics’ off-the-shelf CAR-T cancer therapy shows more remissions, no major safety issues
More of the cancer patients who received CRISPR Therapeutics’ experimental, off-the-shelf CAR-T cell therapy showed…